CStone Pharmaceuticals Closes $150M Series A Financing

CStone Pharmaceuticals Co., Ltd, a Shanghai and Suzhou, China-based biopharmaceutical company developing new treatments in a range of therapeutic areas, closed its Series A round of $150m financing (about 975m RMB).

Backers included Oriza Seed Venture Capital, Boyu Capital, and WuXi Healthcare Ventures.

The company will use the funds to accelerate multiple programs into the clinical stage while at the same time seeking out new innovations from around the world.

Led by new CEO Frank Jiang, MD, PhD, CStone is a research-based, bio-pharmaceutical company covering five therapeutic areas, including oncology, cardiovascular diseases, rheumatoid arthritis, hematology and autoimmune diseases.



Join the discussion